Systemische Endotheldysfunktion bei Patienten mit Pseudoexfoliationssyndrom

Zusammenfassung

Hintergrund: Das Pseudoexfoliationssyndrom (PEX) ist eine häufige altersbezogene Schädigung der extrazellulären Matrix. Es ist eine systemische Erkrankung, gekennzeichnet durch abnorme fibrilläre Ablagerungen in Strukturen des vorderen Augenabschnitts sowie in Haut, Herz, Leber, Lunge, Hirn, Nieren, Gallenblase und Blutgefäßen. Zweck unserer Studie war es, Anzeichen von gestörter Gefäßeendothelfunktion bei PEX-Patienten festzustellen, im Vergleich zu den Kontrollen entsprechenden Alters und Geschlechts. Patienten/Material und Methoden: Es wurden 21 Patienten mit PEX und 21 Kontrollen entsprechenden Alters und Geschlechts prospektiv untersucht. Aufgrund der Reaktion auf die strömungsvermittelte Gefäßerweiterung (Flow-Mediated Dilation, FMD) und die Nitroglyzerin-induzierte Gefäßerweiterung (Nitroglycerin-Mediated Dilation, NMD) wurde die Endothelfunktion der Brachialarterie mittels Ultraschall mit hoher Auflösung beurteilt. Ergebnisse: Patienten mit PEX hatten eine signifikant niedrigere FMD (1,9 – 2,8 versus 4,1 – 3,3 in der Kontrollgruppe, p = 0,02). Auch die NMD war bei PEX-Patienten niedriger als in der Kontrollgruppe, obwohl der Unterschied nicht statistisch signifikant war (10,1 – 5,1 versus 10,8 – 5,8 in der Kontrollgruppe, p < 0,69). Schlussfolgerungen: Unsere Untersuchung zeigte eine statistisch signifikante Assoziation zwischen PEX und systemischer vaskulärer Endotheldysfunktion. Es sind größere klinische Studien notwendig, um die größere kardiovaskuläre Gefährdung von PEX-Patienten zu beweisen.

Abstract

Background: Recent studies have shown that pseudoexfoliation syndrome (PEX) is not limited to the anterior segment of the eye, but also affects different structures, such as blood vessels, heart, liver and lungs. Vascular endothelial dysfunction is associated with an increased cardiovascular risk. The purpose of our study was to evaluate endothelial function of the brachial artery in patients with PEX. Patients/Materials and Methods: We prospectively examined 21 patients with PEX and 21 age- and sex-matched individuals in a control group. Brachial artery endothelial function was assessed by the response to flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD) using high resolution ultrasound. Dilation was expressed as the percent change in diameter relative to the baseline diameter. Results: Patients with PEX had significantly lower FMD (1.9 – 2.8 versus 4.1 – 3.3 in the control group, p = 0.02). NMD in PEX patients was lower than in the control group (10.1 – 5.1 versus 10.8 – 5.8 in the control group, p < 0.69), but the difference was not statistically significant. Conclusions: Our study showed a statistically significant association between PEX and systemic vascular endothelial dysfunction. Larger clinical studies are needed to prove the higher cardiovascular risk in PEX patients.

Glaukom - Biochemie - Pathologie

glaucoma - biochemistry - pathology

Literatur

• 1 Altintas O, Maral H, Yuksel N. et al . Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open angle glaucoma.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 677-683
• 2 Atalar P. Impaired systemic endothelial function in patients with pseudoexfoliation syndrome.  Int Heart Journal Jan. 2006;  47 77-84
• 3 Bojić L, Ermacora R, Polić S. et al . Pseudoexfoliation syndrome and asymptomatic myocardial dysfunction.  Graefes Arch Clin Exp Ophthalmol. 2005;  243 (5) 446-449
• 4 Celermajer D S, Sorensen K E, Bull C. et al . Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.  J Am Coll Cardiol. 1994;  24 (6) 1468-1474
• 5 Celermajer D S, Sorensen K E, Spiegelhalter D J. et al . Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women.  J Am Coll Cardiol. 1994;  24 (2) 471-476
• 6 Chong A Y, Freestone B, Patel J. et al . Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.  Am J Cardiol. 2006;  97 (5) 671-675
• 7 Chowienczyk P J, Watts G F, Cockroft J R. et al . Sex differences in endothelial function in normal and hypercholesterolaemic subjects.  Lancet. 1994;  344 (8918) 305-306
• 8 Citirik M, Acaroglu G, Batman C. et al . A possible link between the pseudoexfoliation syndrome and coronary atrery disease.  Eye. 2007;  21 (1) 11-15
• 9 Consentino F. Endothelial dysfunction in diabetes mellitus.  J Cardiovasc Pharmacol. 1998;  32 (Suppl 3) S54-S61 (Review)
• 10 Conway D S, Pearce L A, Chin B S. et al . Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.  Circulation. 2003;  107 (25) 3141-3145
• 11 Corretti M C, Anderson T J, Benjamin E J. et al . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force.  J Am Coll Cardiol. 2002;  39 257-265
• 12 Fathi R. Noninvasive tests of vascular function and structure: why and how to perform them.  Am Heart J. 2001;  141 694-701 (Rewiev)
• 13 Irkec M. Exfoliation and carotid stiffness.  Br J Ophtalmol. 2006;  90 529-530
• 14 Khail A K, Kuboto T, Tawara A. et al . Early changes in iris blood vessels in exfoliation syndrome.  Curr Eye Res. 1998;  17 1124-1134
• 15 Konstas A G, Marshall G E, Lee W R. Immungold localisation of laminin in normal and exfoliative iris.  Br J Ophthalmol. 1990;  74 450-457
• 16 Konstas A GP, Tsatsos I, Kardasopoulos A. et al . Preoperative features of patients with exfoliation glaucoma and primary open-angle glaucoma. The AHEPA study.  Acta Ophthalmol Scand. 1998;  76 208-212
• 17 Leibovitch I, Kurtz S, Shemesh G. et al . Hyperhomocysteinemia in pseudoexfoliation glaucoma.  J Glaucoma. 2003;  12 36-39
• 18 Linner E, Popovic V, Gottfries C G. et al . The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer’s type.  Acta Ophthalmol Scand. 2001;  79 283-285
• 19 Mitchell P, Wang J J, Smith W. Association of pseudoexfoliaton syndrome with increased vascular risk.  Am J Ophthalmol. 1997;  124 685-687
• 20 Naumann G OH, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist.  Ophthalmology. 1998;  105 951-968
• 21 Puustjarvi T, Blomster H, Kontkanen H. et al . Plasma and aqueous humour levels of homocysteine in exfoliation syndrome.  Graefes Arch Clin Exp Ophthalmol. 2004;  242 749-754
• 22 Ringvold A. Epidemiology of the pseudoexfoliation syndrome.  Acta Ophthalmol Scand. 1999;  77 371-375
• 23 Ringvold A, Blika S, Sandvik L. Pseudo-exfoliation and mortality.  Acta Ophthalmol Scand. 1997;  75 255-566
• 24 Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome.  Surv Ophthalmol. 2001;  45 265-315
• 25 Ritland J S, Egge K, Lydersen S. et al . Exfoliative glaucoma and primary open-angle glaucoma: associations with death causes and comorbidity.  Acta Ophthalmol Scand. 2004;  82 401-404
• 26 Roldán V, Marín F, García-Herola A. et al . Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.  Thromb Res. 2005;  116 (4) 321-325
• 27 Schlötzer-Schrehardt U, Koca M, Naumann G OH. et al . Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder?.  Arch Ophthalmol. 1992;  110 1752-1756
• 28 Schlotzer-Schrehardt U, Küchle M, Nauman G OH. Electron-microscopic identification of pseudoexfoliation material in extrabulbar tissue.  Arch Ophthalmol. 1991;  109 565-570
• 29 Schlötzer-Schrehardt U, Naumann G OH. Ocular and systemic pseudoexfoliation syndrome.  Am J of Ophthalmol. 2006;  141 (5) 921-937
• 30 Schumacher S, Schlötzer-Schrehardt U, Martus P. et al . Pseudoexfoliation syndrome and aneurysms of abdominal aorta.  Lancet. 2001;  357 359-360
• 31 Shrum K R, Hattenhauer M G, Hodge D. Cardiovascular and cerebrovascular mortality associated with ocular pseudoexfoliation.  Am J Ophthalmol. 2000;  129 83-86
• 32 Streeteen B W, Dark A J, Wallace R N. et al . Pseudoexfoliative fibrillopathy in the skin of patients with ocular pseudoexfoliation.  Am J Ophthalmol. 1990;  110 490-499
• 33 Streenten B W, LI Z Y, Wallace R N. et al . Pseudoexfoliation fibrillopathy in visceral organs of patients with pseudoexfoliation syndrome.  Arch Ophthalmol. 1992;  110 1757-1762
• 34 Verma S, Buchanan M R, Anderson T J. Endothelial function testing as a biomarker of vascular disease.  Circulation. 2003;  108 2054-2059
• 35 Vessani R M, Ritch R, Liebmann J M. et al . Plasma homocystein is elevated in patients with exfoliation syndrome.  Am J Ophthalmol. 2003;  136 41-46
• 36 Vesti A, Kivela T. Exfoliation syndrome and exfoliation glaucoma.  Prog Retin Eye Res. 2000;  19 345-368 (Review)
• 37 Vila V, Martínez-Sales V, Almenar L. et al . Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients.  Int J Cardiol. 2007;  doi: 10.1016/j.ijcand.2007.07.010
• 38 Visontai Z, Merisch B, Kollai M. et al . Increase of carotid artery stiffness and decrease of baroreflex sensitivity in exfoliation syndrome and glaucoma.  Br J Ophthalmol. 2006;  90 563-567
• 39 Yüksel N, Anik Y, Altintaş Ö. et al . Magnetic resonance imaging of the brain in patients with pseudoexfoliation syndrome ad glaucoma.  Ophthalmologica. 2006;  220 25-13
• 40 Yüksel N, Karabas L, Arslan A. et al . Ocular Hemodynamics in pseudoexfoliation syndrome and pseudoexfoliation glaucoma.  Ophthalmology. 2001;  108 1043-1049